{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"18.64","upperLimit":"55.93","value":"35.7"},{"groupId":"OG001","lowerLimit":"9.22","upperLimit":"24.95","value":"16.0"},{"groupId":"OG002","lowerLimit":"0.00","upperLimit":"97.50","value":"0.0"},{"groupId":"OG003","lowerLimit":"13.61","upperLimit":"28.52","value":"20.3"}]}],"title":"Week 12"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"24.46","upperLimit":"62.82","value":"42.9"},{"groupId":"OG001","lowerLimit":"15.29","upperLimit":"33.26","value":"23.4"},{"groupId":"OG002","lowerLimit":"0.00","upperLimit":"97.50","value":"0.0"},{"groupId":"OG003","lowerLimit":"19.96","upperLimit":"36.43","value":"27.6"}]}],"title":"Week 24"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"30.65","upperLimit":"69.35","value":"50.0"},{"groupId":"OG001","lowerLimit":"17.09","upperLimit":"35.57","value":"25.5"},{"groupId":"OG002","lowerLimit":"0.00","upperLimit":"97.50","value":"0.0"},{"groupId":"OG003","lowerLimit":"22.88","upperLimit":"39.86","value":"30.9"}]}],"title":"Week 36"}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"94"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"123"}],"units":"Participants"}],"description":"Percentage of participants achieving IGF-1 \\<ULN at weeks 12, 24 \\& 36.","dispersionType":"95% Confidence Interval","groups":[{"description":"These Participants had this GH level at screening","id":"OG000","title":"GH: ≥1 - ≤ 2.5 μg/L"},{"description":"These Participants had this GH level at screening","id":"OG001","title":"GH: > 2.5 μg/L"},{"description":"These Participants were missing GH levels at screening","id":"OG002","title":"GH: Missing"},{"description":"This is the total sum of participants with at screening with various or missing GH levels","id":"OG003","title":"Pasireotide LAR Overall"}],"paramType":"NUMBER","populationDescription":"FAS comprised all patients who had signed informed consent and had been treated with at least one dose of study medication (pasireotide LAR) after enrollment into the study","reportingStatus":"POSTED","timeFrame":"Weeks 12, 24 & 36","title":"Core Phase: Percentage of Participants With IGF-1 <ULN Overall by GH Level at Screening","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}